Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Payables (2019 - 2025)

Vivos Therapeutics' Payables history spans 7 years, with the latest figure at $1.7 million for Q4 2025.

  • Quarterly results put Payables at $1.7 million for Q4 2025, up 52.91% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (up 52.91% YoY), and the annual figure for FY2025 was $1.7 million, up 52.91%.
  • Payables for Q4 2025 was $1.7 million at Vivos Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.5 million in Q1 2024 to a low of $644000.0 in Q3 2022.
  • The 5-year median for Payables is $1.3 million (2021), against an average of $1.4 million.
  • The sharpest move saw Payables skyrocketed 137.27% in 2023, then crashed 51.74% in 2025.
  • Year by year, Payables stood at $920000.0 in 2021, then surged by 53.37% to $1.4 million in 2022, then skyrocketed by 52.02% to $2.1 million in 2023, then plummeted by 48.81% to $1.1 million in 2024, then skyrocketed by 52.91% to $1.7 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $1.7 million, $2.1 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.